2.0, 6.0, 8.0 /). 20

T 0.5 ( ), 0.5 (10.0 /) 0.5 10% 4000 15 4 C. N F 1.

1.0 10.0 / . QC LQC (2.0 /), MQC (6.0 /) HQC (10.0 /) P (=0.0012 -2E-06) F (2

0.9982.
5.0 1.0 /

2.0, 6.0 10.0 / L 98.35%, 97.35%

(ANOVA), (>0.05)
40.0
70.0128 81.3045 /
AUC_{0-24}
56.8765 67.1555 /
AUC_0 70.0128 81.3045 /
K_{el}
0.0899 0.0899,

C

HPLC UV



AUC C

40.0 N

(T/R) AUC_0, AUC_0

C

80-125% (

). B

H

R.

References

1. Wolozin B, Wang SW, Li NC, Lee A, Lee A, et al. (2007). Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Medicine 5: 20.

2. Barrett B, Huclova J, Borek-Dohalsky V, Nemec B, Jelinek I (2006) Validated HPLC–MS/MS method for simultaneous determination of simvastatin and simvastatin hydroxy acid in human plasma. J Pharm Biomed Anal 41: 517-526.

3. Carlucci G, Mazzeo P, Biordi L, Bologna M (1991) Simultaneous determination of simvastatin and its hydroxy acid form in human plasma by high-performance liquid chromatography with UV detection. J Pharm Biomed Anal 10: 693-697.

4. Ali H, Nazzal S (2009) Development and validation of a reversed-phase HPLC method for the simultaneous analysis of simvastatin and tocotrienols in combined dosage forms. J Pharm Biomed Anal 49: 950-956.

5. Novakova L, Satinsky D, Solich P (2008) HPLC methods for the determination of simvastatin and atorvastatin TrAC Trends in Analytical Chemistry 27: 352-367.

6. Hefnawy M, Al-Omar M, Julkhuf S (2009) Rapid and sensitive simultaneous determination of ezetimibe and simvastatin from their combination drug products by monolithic silica high-performance liquid chromatographic column. J Pharm Biomed Anal 50: 527-534.

7. Vuletic M, Cindric M, Koruznjak JD (2005) Identifcation of unknown impurities in simvastatin substance and tablets by liquid chromatography/tandem mass spectrometry. J Pharm Biomed Anal 37: 715-721.

8. Guidance for Industry, Bioanalytical Method Validation (2001) Rockville, Maryland: U.S. Department of Health and Human Services. Food ® פ נ ף ו א ו'